Study of Resistance Mechanisms Against Lapatinib in Patients With ErbB-2-Positive Breast Cancers
- To identify secondary ErbB2 mutations in tumor tissue samples from patients with
ErbB2-positive breast cancer treated with lapatinib ditosylate.
- To investigate ErbB2 copy number changes and expression levels.
- To determine abnormalities of other pathways (e.g., c-MET and PI3K) as potential
mechanisms of resistance.
OUTLINE: Previously collected tumor tissue samples* are obtained for genetic analysis
studies. Samples are analyzed for secondary ErbB2 mutations by nested PCR; ErbB2 copy number
changes by quantitative PCR and standard histological FISH; and ErbB2 expression levels by
quantitative RT-PCR and IHC. Patients also undergo blood sample collection for extraction of
DNA (as normal control DNA) and isolation of EpCAM-positive circulating tumor cells using
immunomagnetic cell separation technology. Additional research studies may include
mutational and amplification analysis of the c-MET and PI3K pathways.
NOTE: *Patients may undergo biopsy if a post-treatment tumor tissue sample is unavailable.
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Secondary ErbB2 mutations
Thomas Budd, MD
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
United States: Federal Government
|Mercy Cancer Center at Mercy Medical Center||Canton, Ohio 44708|
|Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|
|Lake/University Ireland Cancer Center||Mentor, Ohio 44060|
|Geauga Regional Hospital||Chardon, Ohio 44024|
|Southwest General Health Center||Middleburgh Heights, Ohio 44130|
|UHHS Chagrin Highlands Medical Center||Orange Villager, Ohio 44122|
|University Suburban Health Center||South Euclid, Ohio 44121|
|UHHS Westlake Medical Center||Westlaker, Ohio 44145|
|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center||Cleveland, Ohio 44195|